Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )
ClinicalTrials.gov Identifier:
NCT00339885
First received: June 19, 2006
Last updated: August 12, 2016
Last verified: August 2016

June 19, 2006
August 12, 2016
March 1995
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00339885 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus
Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus

The aim of the project is to positionally clone susceptibility genes for NIDDM. Patients will be ascertained in Finland from previous health surveys and hospital discharge records. Approximately 400 affected sib pairs will be collected. Families will be chosen who have, at most, one parent with NIDDM no history of IDDM. A clinical examination will be undertaken on family members and blood drawn for DNA isolation. Covariates such as body weight, blood pressure, lipid levels and urinary albumin will also be measured. The unaffected spouse and children of a subset of probands will be invited to undergo a frequently-sampled intravenous glucose tolerance test (FSIGT) to measure parameters of pancreatic function and peripheral insulin resistance (IR). A number of unrelated elderly non-diabetic subjects will also be identified to conduct a population-based association analysis.

The FSIGT analysis will be performed in Los Angeles. The DNA will be shipped to Bethesda where a total genomic scan will be performed using semi-automated fluorescence-based genotyping technology. Data from Bethesda, Los Angeles and Finland will be sent to Ann Arbor where parametric and non-parametric methods will be used to analyse both discrete traits such as NIDDM and intermediate traits like IR.

The Finland-United States investigation of NIDDM (FUSION) study is a long-term effort to

identify susceptibility genes for Type 2 diabetes (T2D) and associated quantitative traits. This

involves the phenotyping and DNA analysis of thousands of individuals living in Finland, utilizing a study design that was originally based on affected sib pairs. The majority of these samples have already been subjected to a genome scan using microsatellite markers and the original FUSION samples. Additionally, thousands of other northern European cases and controls have been subjected to genome-wide association (GWA) analysis and/or fine mapping as part of the FUSION study. More recently, the opportunity provided by the lowered sequencing costs have allowed targeted and/or whole genome sequencing of many of these individuals.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Non-Insulin Dependent Diabetes Mellitus
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60000
Not Provided
Not Provided
  • No eligibility criteria listed.
Both
12 Months and older   (Child, Adult, Senior)
Yes
Contact: Ann C. M. Smith (301) 435-5475 acmsmith@nhgri.nih.gov
Contact: Lori Bonnycastle, Ph.D. (301) 594-9206 lbonnyca@mail.nih.gov
Finland,   Germany,   Norway
United States
 
NCT00339885
999995030, OH95-HG-N030
Not Provided
Not Provided
Not Provided
National Human Genome Research Institute (NHGRI)
National Human Genome Research Institute (NHGRI)
Not Provided
Principal Investigator: Lori Bonnycastle, Ph.D. National Human Genome Research Institute (NHGRI)
National Institutes of Health Clinical Center (CC)
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP